Development and validation of a hypoxia-associated signature for lung adenocarcinoma

Hypoxia is common in non-small cell lung cancer (NSCLC) and an attractive therapeutic target. As hypoxia-targeting treatments are effective in patients with the most hypoxic tumours, we aimed to develop a lung adenocarcinoma (LUAD) hypoxia-related gene expression signature. RNAseq was used to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Brian, Khan, Mairah T., Choudhury, Ananya, Salem, Ahmed, West, Catharine M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789914/
https://www.ncbi.nlm.nih.gov/pubmed/35079065
http://dx.doi.org/10.1038/s41598-022-05385-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789914/
https://www.ncbi.nlm.nih.gov/pubmed/35079065
http://dx.doi.org/10.1038/s41598-022-05385-7

Ejemplares similares